Form 4: Supernus Pharmaceuticals Director Newhall Receives Stock Options and Restricted Stock Units

Director Charles W. Newhall III receives stock options and restricted stock units from Supernus Pharmaceuticals.

Summary

• On February 19, 2025, Charles W. Newhall III, a director of Supernus Pharmaceuticals, received stock options to purchase 7,296 shares of common stock at an exercise price of $33.52, vesting on February 19, 2026 and expiring on February 19, 2035.
• Newhall also received 4,475 restricted stock units (RSUs), each representing the right to receive one share of Supernus common stock upon vesting, which will occur on February 19, 2026.
• Following these transactions, Newhall directly owns 130,275 shares of Supernus common stock, 7,296 stock options, and 4,475 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and generally viewed favorably as it aligns the director's interests with those of the shareholders. There are no indications of negative news or concerns.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Grants of stock options and restricted stock units are common practices in the pharmaceutical industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• The vesting schedules are generally in line with industry standards, designed to retain talent and align interests with long-term shareholder value creation.
• Comparable companies such as Jazz Pharmaceuticals and Alkermes also utilize stock options and RSUs as part of their executive compensation plans.

Stakeholder Impact

• Shareholders: Aligns director's interests with shareholder value.
• Employees: May boost morale knowing leadership is incentivized.
• Director: Provides additional compensation and ownership stake.

Key Dates

Keywords

Supernus Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, Securities